View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Maria Vara
  • Maria Vara

BONESUPPORT: 2025 Trim; Spine optionality kicks in

Following Q2 earnings, we revisited our expectations across all business segments, leading to a 9% 2025E sales cut, majorly driven by FX headwinds on US sales, while country-specific policies in EUROW led to softer-than-expected H1 growth. Our long-term thesis remains unchanged, and we see improvin

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
Maria Vara
  • Maria Vara

BONESUPPORT: Q2 US momentum in line; softer EU and FX weigh on EBIT

BONESUPPORT reported Q2 2025 net sales of SEK 284.4m, slightly below CSS SEK 291m (Stifel est. SEK 299m), with the deviation primarily due to a softer-than-expected European performance. Growth was led by the US, which grew 36% YoY reported (49% CER), though it fell -2%, and -4% vs CSS and our expe

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson

Bonesupport Holding AB: 1 director

A director at Bonesupport Holding AB bought 2,000 shares at 273.000SEK and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
Maria Vara
  • Maria Vara

BONESUPPORT: Q1 revenue beats, but FX-driven EBIT miss masks solid mom...

BONESUPPORT reported a robust Q1, with net sales of SEK283.5m beating CSS SEK276m and driven by CERAMENT G sales of SEK178m in North America — well ahead of the SEK160m forecast. Gross margin remained best-in-class at 92.6%, slightly above expectations, underscoring the strength of the business mod

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
Maria Vara
  • Maria Vara

BONESUPPORT: Model Update – Reiterate BUY and SEK400 PT

We have updated our model, rolling it over after Q4 results and in preparation for Q1 2025, to be reported on 24 April. While our long-term conviction for BONESUPPORT products has not changed, we have slightly softened our 2025 EU sales growth assumptions from 39% to 22% YoY growth following a slow

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Zimmer Biomet Holdings, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 March 2025 in which we reassessed the appropriateness of the ratings in the...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
Maria Vara
  • Maria Vara

BONESUPPORT: Closing a solid 2024

2024 saw BONESUPPORT further accelerate its market leadership with Q4 sales reaching SEK257m—up 49% YoY—driving FY sales to SEK898.7m (52% YoY), in line with guidance of 50% topline growth. In North America, CERAMENT G continued its strong performance, rising by approximately SEK22m QoQ to reach ar

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson

Moody's Ratings assigns Baa2 rating to Zimmer's new senior unsecured n...

Moody's Ratings (Moody's) assigned a Baa2 rating to Zimmer Biomet Holdings, Inc. ("Zimmer") proposed $3 billion senior unsecured notes. At the same time, we assigned a (P)Baa2 rating to Zimmer's senior unsecured shelf registration. There are no changes to the existing Baa2 senior unsecured rating. T...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch